Reaction

Asthmatic Crisis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,609 reports · 52 co-occurring drugs

As of the last recalculation, Asthmatic Crisis appears in 3,609 FAERS reports alongside 52 co-occurring drug terms. The strongest observed disproportionality signal is MEPOLIZUMAB (PRR 86.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Mepolizumab61686.087.1
Omalizumab76665.566.1
Fluticasone Furoate6732.532.7
Tiotropium Bromide Inhalation Spray6031.431.5
Budesonide And Formoterol Fumarate Dihydrate44229.829.9
Montelukast35426.927.0
Ciclesonide6226.726.8
Benralizumab8525.125.2
Ipratropium Bromide14524.424.5
Montelukast Sodium32616.916.9
Albuterol28414.714.8
Desloratadine2714.614.7
Tiotropium Bromide28512.913.0
Budesonide12612.712.8
Fluticasone Propionate Nasal6512.612.6
Albuterol Sulfate49711.011.1
Theophylline2010.110.1
Theophylline Anhydrous209.39.4
Salmeterol Xinafoate138.78.7
Mometasone278.58.6
Captopril148.48.4
Loratadine Oral617.37.3
Mometasone Furoate507.07.0
Azithromycin426.16.1
Rosuvastatin Calcium296.06.0
Valsartan Oral555.95.9
Azithromycin Monohydrate425.95.9
Fexofenadine165.65.6
Palivizumab145.35.3
Fluticasone Propionate1155.25.2
Fluticasone Furoate And Vilanterol Trifenatate325.25.2
Losartan1515.25.2
Esomeprazole524.94.9
Azithromycin Dihydrate484.84.8
Umeclidinium74.54.5
Budesonide, Glycopyrrolate, And Formoterol Fumarate84.44.4
Valsartan734.14.1
Enalapril384.04.0
Fluticasone Propionate And Salmeterol Xinafoate403.93.9
Valsartan And Hydrochlorothiazide93.83.8
Fexofenadine Hcl63.73.7
Iron Sucrose63.63.6
Iohexol53.53.5
Loratadine633.43.4
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate223.13.1
Bleomycin Sulfate52.82.8
Eptinezumab-Jjmr42.52.5
Somatropin241.91.9
Bimatoprost91.81.8
Sofosbuvir61.81.8
Dupilumab630.70.7
Salicylic Acid30.30.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.